Carna Biosciences (TSE:4572) Other Current Liabilities: 円9.9 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4572 Carna Biosciences Inc TSE:4572
37 GF Score
Price 円311.00
GF Value 円186.88
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Carna Biosciences Other Current Liabilities?

Carna Biosciences TSE:4572 -7.16% 37 Other Current Liabilities is 円9.9 Mil as of Dec. 2025. GuruFocus rates TSE:4572 with a GF Score™ of 37/100 and a GF Value™ of 円186.88 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Carna Biosciences's other current liabilities for the quarter that ended in Dec. 2025 was 円9.9 Mil.

Carna Biosciences's quarterly other current liabilities declined from Jun. 2025 (円28.6 Mil) to Sep. 2025 (円21.4 Mil) and declined from Sep. 2025 (円21.4 Mil) to Dec. 2025 (円9.9 Mil).

Carna Biosciences's annual other current liabilities declined from Dec. 2023 (円29.8 Mil) to Dec. 2024 (円12.6 Mil) and declined from Dec. 2024 (円12.6 Mil) to Dec. 2025 (円9.9 Mil).

Carna Biosciences Other Current Liabilities Related Terms

Carna Biosciences Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences Other Current Liabilities Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 200.80 16.66 29.78 12.60 9.95

Carna Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.79 28.61 21.36 9.95 17.15
TSE:4572
37GF Score
Carna Biosciences Inc TSE:4572
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carna Biosciences Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of 円9.9 Mil mean?
Carna Biosciences (TSE:4572) has a Other Current Liabilities of 円9.9 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Carna Biosciences.
Is Carna Biosciences' Other Current Liabilities too high?
Carna Biosciences' current Other Current Liabilities is 円9.9 Mil. Overall, Carna Biosciences has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Other Current Liabilities compare to VRTX and REGN?
Carna Biosciences' Other Current Liabilities of 円9.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Carna Biosciences. Carna Biosciences's current Other Current Liabilities is 円9.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円186.88, compared to a current price of 円311.00 — trading 66.4% above its estimated fair value. The current Other Current Liabilities is 円9.9 Mil. Carna Biosciences' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Other Current Liabilities is 円9.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円311.00 is trading 66.4% above its estimated GF Value™ of 円186.88. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • Other Current Liabilities: 円9.9 Mil
  • GF Value™: 円186.88 vs. price of 円311.00 (66.4% above fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
37GF Score

Get the complete analysis for TSE:4572

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円311.00
Price
円186.88
GF Value